Viva Biotech Holdings (HKG:1873)
Hong Kong
· Delayed Price · Currency is HKD 1.670
-0.040 (-2.34%)
Apr 29, 2026, 4:08 PM HKT
Viva Biotech Holdings Revenue
In the year 2025, Viva Biotech Holdings had annual revenue of 1.73B CNY, down -12.95%. Viva Biotech Holdings had revenue of 897.57M in the half year ending December 31, 2025, a decrease of -11.43%.
Revenue
1.73B CNY
Revenue Growth
-12.95%
P/S Ratio
1.88
Revenue / Employee
797.35K CNY
Employees
2,169
Market Cap
3.61B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.73B | -257.21M | -12.95% |
| Dec 31, 2024 | 1.99B | -168.93M | -7.84% |
| Dec 31, 2023 | 2.16B | -224.05M | -9.42% |
| Dec 31, 2022 | 2.38B | 275.55M | 13.10% |
| Dec 31, 2021 | 2.10B | 1.41B | 201.90% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Antengene Corporation | 117.22M |
| Mirxes Holding Company | 166.32M |
| BioDlink International Company | 831.99M |
| TYK Medicines | 117.25K |
| Clover Biopharmaceuticals | 3.90M |
| Qyuns Therapeutics | 897.99M |
| Shandong Boan Biotechnology | 873.36M |
| Jiangsu Recbio Technology | 14.16M |
Viva Biotech Holdings News
- 4 weeks ago - Viva Biotech Announces 2025 Annual Results: AI-Driven Drug Discovery Reinforces Industry Leadership, CDMO Commercial Products Enter Rapid Scale-Up - PRNewsWire
- 6 weeks ago - Viva Biotech Accelerates AI-Driven Drug Discovery and Advance the 'Lab-in-the-Loop' with NVIDIA - PRNewsWire
- 4 months ago - Adventures in DMPK: Viva Biotech's One-Stop Pharmacology Platform Cross New Modalities - PRNewsWire
- 4 months ago - Viva Biotech's invested and incubated company, Arthrosi, has entered into an acquisition agreement with Sobi for a total transaction value of up to US$1.5 billion. - PRNewsWire
- 7 months ago - Viva Biotech Receives Frost & Sullivan's 2025 APAC Technology Innovation Leadership Recognition in the Integrated Intelligent Drug Discovery Industry - PRNewsWire
- 8 months ago - Unlocking the Potential of Cyclic Peptide Therapeutics: Viva Biotech's Discovery Insights - PRNewsWire
- 8 months ago - Viva Biotech Announces Its 2025 Interim Results: CRO Revenue Returned to Positive Growth, New CDMO Commercialization Projects Showed Promising Growth - PRNewsWire
- 1 year ago - Viva Biotech's Wholly-Owned Subsidiary Langhua Pharmaceutical Successfully Passes U.S. FDA On-Site Inspection - PRNewsWire